{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06204679",
            "orgStudyIdInfo": {
                "id": "AT-01B-005"
            },
            "organization": {
                "fullName": "Atea Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir",
            "officialTitle": "A Phase 1, Open-Label Study to Assess Comparative Bioavailability and Effect of Food on a Prototype Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir Versus Individual Dosage Forms Taken Concomitantly in Healthy Adult Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "pharmacokinetics-of-fixed-dose-combination-tablet-of-bemnifosbuvir-and-ruzasvir"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-02-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-02-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-02",
            "studyFirstSubmitQcDate": "2024-01-11",
            "studyFirstPostDateStruct": {
                "date": "2024-01-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Atea Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects"
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteer Study"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "FDC Fasting",
                    "type": "EXPERIMENTAL",
                    "description": "Day 1, Day 7, Day 13",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions"
                    ]
                },
                {
                    "label": "FDC Fed",
                    "type": "EXPERIMENTAL",
                    "description": "Day 1, Day 7, Day 13",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions"
                    ]
                },
                {
                    "label": "Reference Fasting",
                    "type": "EXPERIMENTAL",
                    "description": "Day 1, Day 7, Day 13",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions",
                    "description": "A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)",
                    "armGroupLabels": [
                        "FDC Fasting"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions",
                    "description": "A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)",
                    "armGroupLabels": [
                        "FDC Fed"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions",
                    "description": "Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations",
                    "armGroupLabels": [
                        "Reference Fasting"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK) of FDC compared to reference:(Cmax)",
                    "description": "Maximum plasma concentration (Cmax)",
                    "timeFrame": "Day 1, Day 7, Day 13"
                },
                {
                    "measure": "Pharmacokinetics (PK) of FDC compared to reference:(AUC)",
                    "description": "Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Day 1, Day 7, Day 13"
                },
                {
                    "measure": "Food effect of Fixed Dose Combination of Bemnifosbuvir (BEM)/Ruzasvir (RZR):(Cmax)",
                    "description": "Maximum plasma concentration (Cmax)",
                    "timeFrame": "Day 1, Day 7, Day 13"
                },
                {
                    "measure": "Food effect of Fixed Dose Combination of Bemnifosbuvir (BEM)/Ruzasvir (RZR):(AUC)",
                    "description": "Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Day 1, Day 7, Day 13"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug.\n* Minimum body weight of 50 kg and body mass index (BMI) of 18-30 kg/m2.\n* Willing to comply with the study requirements and to provide written informed consent.\n\nExclusion Criteria:\n\n* Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2.\n* Abuse of alcohol or drugs.\n* Use of other investigational drugs within 28 days of dosing.\n* Concomitant use of prescription medications, or systemic over-the-counter medications.\n* Other clinically significant medical conditions or laboratory abnormalities.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Atea Study Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "888-481-1607",
                    "email": "ateaclinicaltrials@ateapharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Atea Study Site",
                    "status": "RECRUITING",
                    "city": "Cypress",
                    "state": "California",
                    "zip": "90630",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.81696,
                        "lon": -118.03729
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000621654",
                    "term": "Ruzasvir"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M263854",
                    "name": "Ruzasvir",
                    "asFound": "PIM",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}